Regulation of the PTEN/PI3K/AKT pathway in RCC using the active compounds of natural products <em>in vitro</em>

Wang,Xue; Xie,Zhenhua; Lou,Zhongguan; Chen,Yulu; Huang,Shuaishuai; Ren,Yu; Weng,Guobin; Zhang,Shuwei

doi:10.3892/mmr.2021.12406

Regulation of the PTEN/PI3K/AKT pathway in RCC using the active compounds of natural products in vitro

Authors:
- Xue Wang
- Zhenhua Xie
- Zhongguan Lou
- Yulu Chen
- Shuaishuai Huang
- Yu Ren
- Guobin Weng
- Shuwei Zhang
View Affiliations

Affiliations: Urology and Nephrology Institute of Ningbo University, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, P.R. China
Published online on: September 3, 2021 https://doi.org/10.3892/mmr.2021.12406
Article Number: 766
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Since Professor Tu Youyou won the 2015 Nobel Prize in Physiology and Medicine for the discovery of artemisinin, which is used to treat malaria, increased attention has been paid to the extracts obtained from plants, in order to analyze their biological activities, particularly with regard to their antitumor activity. Therefore, the present study explored the biochemical properties of seven natural plant extracts on renal cell carcinoma (RCC). 786‑O and OS‑RC‑2 cells were cultured and treated with different concentrations of the extracts. Then, cell viability, the IC₅₀ value and proliferation was determined using a Cell Counting Kit‑8 assay. Apoptosis and cell cycle distribution were evaluated via flow cytometry. The expression levels of proteins were assessed using western blotting, and cellular morphology was observed using a light microscope. The results showed that sophoricoside, aucubin, notoginsenoside R1 and ginsenoside Rg1 did not exhibit a cytotoxic effect on RCC cells, whereas ginsenoside Re and allicin exhibited a very slight inhibitory effect. Naringenin possessed the highest activity of the analyzed extracts. The IC50 values of naringenin on 786‑O and OS‑RC‑2 cells were 8.91±0.33 and 7.78±2.65 µM, respectively. In addition, naringenin notably inhibited the proliferation of RCC cells by decreasing Ki67 expression, blocked cell cycle progression in the G₂ phase by regulating expression of cell cycle proteins, and increased apoptosis by upregulating caspase‑8 expression, downregulating Bcl‑2 expression and altering the cellular morphology. Furthermore, naringenin inhibited cell proliferation and promoted apoptosis by upregulating the expression of PTEN at the protein level, downregulated the expression of PI3K and phosphorylated‑(p‑)AKT, but did not affect the expression of AKT, mTOR or p‑mTOR. The seven plant extracts analyzed showed differing degrees of anti‑RCC activity. Sophoricoside, aucubin, notoginsenoside R1 and ginsenoside Rg1 did not exhibit notable anti‑RCC activity, whereas the effect of ginsenoside Re and allicin on RCC was considerably weak. However, naringenin showed potent anti‑proliferative, apoptosis inducing and cell cycle arresting activity on RCC cells via regulation of the PTEN/PI3K/AKT signaling pathway.

View Figures

View References

1	Zhuang H, Meng X, Li Y, Wang X, Huang S, Liu K, Hehir M, Fang R, Jiang L, Zhou JX, et al: Cyclic AMP responsive element-binding protein promotes renal cell carcinoma proliferation probably via the expression of spindle and kinetochore-associated protein 2. Oncotarget. 7:16325–16337. 2016. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
3	Haque I, Subramanian A, Huang CH, Godwin AK, Van Veldhuizen PJ, Banerjee S and Banerjee SK: The role of compounds derived from natural supplement as anticancer agents in renal cell carcinoma: A review. Int J Mol Sci. 19:1072017. View Article : Google Scholar : PubMed/NCBI
4	Mendiratta P, Rini BI and Ornstein MC: Emerging immunotherapy in advanced renal cell carcinoma. Urol Oncol. 35:687–693. 2017. View Article : Google Scholar : PubMed/NCBI
5	Wang X, Huang S, Xin X, Ren Y, Weng G and Wang P: The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110gamma catalytic subunit of PI3Kγ. Acta Pharm. 69:111–119. 2019. View Article : Google Scholar : PubMed/NCBI
6	Ji HF, Li XJ and Zhang HY: Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep. 10:194–200. 2009. View Article : Google Scholar : PubMed/NCBI
7	Reddy D, Kumavath R, Tan TZ, Ampasala DR and Kumar AP: Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers. Life Sci. 241:1171472020. View Article : Google Scholar : PubMed/NCBI
8	Krushkal J, Negi S, Yee LM, Evans JR, Grkovic T, Palmisano A, Fang J, Sankaran H, McShane LM, Zhao Y and O'Keefe BR: Molecular genomic features associated with in vitro response of the NCI-60 cancer cell line panel to natural products. Mol Oncol. 15:381–406. 2021. View Article : Google Scholar : PubMed/NCBI
9	Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L, Schwaiger S, Heiss EH, et al: Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv. 33:1582–1614. 2015. View Article : Google Scholar : PubMed/NCBI
10	Fang J, Wu Z, Cai C, Wang Q, Tang Y and Cheng F: Quantitative and systems pharmacology. 1. in silico prediction of drug-target interactions of natural products enables new targeted cancer therapy. J Chem Inf Model. 57:2657–2671. 2017. View Article : Google Scholar : PubMed/NCBI
11	Ha MW, Song BR, Chung HJ and Paek SM: Design and synthesis of anti-cancer chimera molecules based on marine natural products. Mar Drugs. 17:5002019. View Article : Google Scholar : PubMed/NCBI
12	Czarnik AW and Keene JD: Combinatorial chemistry. Curr Biol. 8:R705–R707. 1998. View Article : Google Scholar : PubMed/NCBI
13	Siddiqui M and Rajkumar SV: The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 87:935–943. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kang Q, Gong J, Wang M, Wang Q, Chen F and Cheng KW: 6-C-(E-Phenylethenyl)naringenin attenuates the stemness of hepatocellular carcinoma cells by suppressing wnt/beta-catenin signaling. J Agric Food Chem. 67:13939–13947. 2019. View Article : Google Scholar : PubMed/NCBI
15	O'Brien CA, Kreso A and Jamieson CH: Cancer stem cells and self-renewal. Clin Cancer Res. 16:3113–3120. 2010. View Article : Google Scholar : PubMed/NCBI
16	Sui M, Zhang H, Di X, Chang J, Shen Y and Fan W: G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy. Radiother Oncol. 104:243–248. 2012. View Article : Google Scholar : PubMed/NCBI
17	Sezer ED, Oktay LM, Karadadas E, Memmedov H, Gunel NS and Sözmen E: Assessing anticancer potential of blueberry flavonoids, quercetin, kaempferol, and gentisic acid, through oxidative stress and apoptosis parameters on HCT-116 cells. J Med Food. 22:1118–1126. 2019. View Article : Google Scholar : PubMed/NCBI
18	Deleuze A, Saout J, Dugay F, Peyronnet B, Mathieu R, Verhoest G, Bensalah K, Crouzet L, Laguerre B, Belaud-Rotureau MA, et al: Immunotherapy in renal cell carcinoma: The future is now. Int J Mol Sci. 21:25322020. View Article : Google Scholar : PubMed/NCBI
19	Gu B, Ding Q, Xia G and Fang Z: EGCG inhibits growth and induces apoptosis in renal cell carcinoma through TFPI-2 overexpression. Oncol Rep. 21:635–640. 2009.PubMed/NCBI
20	Meng FD, Li Y, Tian X, Ma P, Sui CG, Fu LY and Jiang YH: Synergistic effects of snail and quercetin on renal cell carcinoma Caki-2 by altering AKT/mTOR/ERK1/2 signaling pathways. Int J Clin Exp Pathol. 8:6157–6168. 2015.PubMed/NCBI
21	Batova A, Altomare D, Creek KE, Naviaux RK, Wang L, Li K, Green E, Williams R, Naviaux JC, Diccianni M and Yu AL: Englerin A induces an acute inflammatory response and reveals lipid metabolism and ER stress as targetable vulnerabilities in renal cell carcinoma. PLoS One. 12:e01726322017. View Article : Google Scholar : PubMed/NCBI
22	Hamedani Y, Chakraborty S, Sabarwal A, Pal S, Bhowmick S and Balan M: Novel Honokiol-eluting PLGA-based scaffold effectively restricts the growth of renal cancer cells. PLoS One. 15:e02438372020. View Article : Google Scholar : PubMed/NCBI
23	Zhang T, Zhao L, Zhang TT, Wu W, Liu J, Wang X, Wan Y, Geng H, Sun X, Qian W and Yu D: Curcumin negatively regulates cigarette smoke-induced renal cell carcinoma epithelial-mesenchymal transition through the ERK5/AP-1 pathway. Onco Targets Ther. 13:9689–9700. 2020. View Article : Google Scholar : PubMed/NCBI
24	Dai L, Chen L, Wang W and Lin P: Resveratrol inhibits ACHN cells via regulation of histone acetylation. Pharm Biol. 58:231–238. 2020. View Article : Google Scholar : PubMed/NCBI
25	Kim BH, Chung EY, Min BK, Lee SH, Kim MK, Min KR and Kim Y: Anti-inflammatory action of legume isoflavonoid sophoricoside through inhibition on cyclooxygenase-2 activity. Planta Med. 69:474–476. 2003. View Article : Google Scholar : PubMed/NCBI
26	Wu C, Luan H, Wang S, Zhang X, Wang R, Jin L, Guo P and Chen X: Modulation of lipogenesis and glucose consumption in HepG2 cells and C2C12 myotubes by sophoricoside. Molecules. 18:15624–15635. 2013. View Article : Google Scholar : PubMed/NCBI
27	Yang Z, Wu QQ, Xiao Y, Duan MX, Liu C, Yuan Y, Meng YY, Liao HH and Tang QZ: Aucubin protects against myocardial infarction-induced cardiac remodeling via nNOS/NO-regulated oxidative stress. Oxid Med Cell Longev. 2018:43279012018. View Article : Google Scholar : PubMed/NCBI
28	Liu H, Yang J, Yang W, Hu S, Wu Y, Zhao B, Hu H and Du S: Focus on notoginsenoside R1 in metabolism and prevention against human diseases. Drug Des Devel Ther. 14:551–565. 2020. View Article : Google Scholar : PubMed/NCBI
29	Shen B, Zhao C, Wang Y, Peng Y, Cheng J, Li Z, Wu L, Jin M and Feng H: Aucubin inhibited lipid accumulation and oxidative stress via Nrf2/HO-1 and AMPK signalling pathways. J Cell Mol Med. 23:4063–4075. 2019. View Article : Google Scholar : PubMed/NCBI
30	Qin Q, Lin N, Huang H, Zhang X, Cao X, Wang Y and Li P: Ginsenoside Rg1 ameliorates cardiac oxidative stress and inflammation in streptozotocin-induced diabetic rats. Diabetes Metab Syndr Obes. 12:1091–1103. 2019. View Article : Google Scholar : PubMed/NCBI
31	Li W, Li G, She W, Hu X and Wu X: Targeted antitumor activity of Ginsenoside (Rg1) in paclitaxel-resistant human nasopharyngeal cancer cells are mediated through activation of autophagic cell death, cell apoptosis, endogenous ROS production, S phase cell cycle arrest and inhibition of m-TOR/PI3K/AKT signalling pathway. J BUON. 24:2056–2061. 2019.PubMed/NCBI
32	Hou Y, Gu D, Peng J, Jiang K, Li Z, Shi J, Yang S, Li S and Fan X: Ginsenoside Rg1 regulates liver lipid factor metabolism in NAFLD model rats. ACS Omega. 5:10878–10890. 2020. View Article : Google Scholar : PubMed/NCBI
33	Nan B, Yang C, Li L, Ye H, Yan H, Wang M and Yuan Y: Allicin alleviated acrylamide-induced NLRP3 inflammasome activation via oxidative stress and endoplasmic reticulum stress in Kupffer cells and SD rats liver. Food Chem Toxicol. 148:1119372021. View Article : Google Scholar : PubMed/NCBI
34	Salehi B, Fokou PVT, Sharifi-Rad M, Zucca P, Pezzani R, Martins N and Sharifi-Rad J: The therapeutic potential of naringenin: A review of clinical trials. Pharmaceuticals (Basel). 12:112019. View Article : Google Scholar : PubMed/NCBI
35	Huang B, Hu P, Hu A, Li Y, Shi Q, Huang J, Jiang Q, Xu S, Li L and Wu Q: Naringenin attenuates carotid restenosis in rats after balloon injury through its anti-inflammation and anti-oxidative effects via the RIP1-RIP3-MLKL signaling pathway. Eur J Pharmacol. 855:167–174. 2019. View Article : Google Scholar : PubMed/NCBI
36	Chanput W, Krueyos N and Ritthiruangdej P: Anti-oxidative assays as markers for anti-inflammatory activity of flavonoids. Int Immunopharmacol. 40:170–175. 2016. View Article : Google Scholar : PubMed/NCBI
37	Pinho-Ribeiro FA, Zarpelon AC, Fattori V, Manchope MF, Mizokami SS, Casagrande R and Verri WA Jr: Naringenin reduces inflammatory pain in mice. Neuropharmacology. 105:508–519. 2016. View Article : Google Scholar : PubMed/NCBI
38	Zhang C, Zeng W, Yao Y, Xu B, Wei X, Wang L, Yin X, Barman AK, Zhang F, Zhang C, et al: Naringenin ameliorates radiation-induced lung injury by lowering IL-1beta level. J Pharmacol Exp Ther. 366:341–348. 2018. View Article : Google Scholar : PubMed/NCBI
39	Joshi R, Kulkarni YA and Wairkar S: Pharmacokinetic, pharmacodynamic and formulations aspects of Naringenin: An update. Life Sci. 215:43–56. 2018. View Article : Google Scholar : PubMed/NCBI
40	Latif AD, Gonda T, Vagvolgyi M, Kúsz N, Kulmány A, Ocsovszki I, Zomborszki ZP, Zupkó I and Hunyadi A: Synthesis and in vitro antitumor activity of naringenin oxime and oxime ether derivatives. Int J Mol Sci. 20:21842019. View Article : Google Scholar : PubMed/NCBI
41	Tarantino G, Citro V and Capone D: Nonalcoholic fatty liver disease: A challenge from mechanisms to therapy. J Clin Med. 9:152019. View Article : Google Scholar : PubMed/NCBI
42	Fu S, Zhang Y, Shi J, Hao D and Zhang P: Identification of gene-phenotype connectivity associated with flavanone naringenin by functional network analysis. PeerJ. 7:e66112019. View Article : Google Scholar : PubMed/NCBI
43	Hermawan A, Ikawati M, Jenie RI, Khumaira A, Putri H, Nurhayati IP, Angraini SM and Muflikhasari HA: Identification of potential therapeutic target of naringenin in breast cancer stem cells inhibition by bioinformatics and in vitro studies. Saudi Pharm J. 29:12–26. 2021. View Article : Google Scholar : PubMed/NCBI
44	Han KY, Chen PN, Hong MC, Hseu YC, Chen KM, Hsu LS and Chen WJ: Naringenin attenuated prostate cancer invasion via reversal of epithelial-to-mesenchymal transition and inhibited uPA activity. Anticancer Res. 38:6753–6758. 2018. View Article : Google Scholar : PubMed/NCBI
45	Tan Z, Sun Y, Liu M, Xia L, Cao F, Qi Y and Song Y: Naringenin inhibits cell migration, invasion, and tumor growth by regulating circFOXM1/miR-3619-5p/SPAG5 axis in lung cancer. Cancer Biother Radiopharm. 27:10892020.
46	Choi J, Lee DH, Jang H, Park SY and Seol JW: Naringenin exerts anticancer effects by inducing tumor cell death and inhibiting angiogenesis in malignant melanoma. Int J Med Sci. 17:3049–3057. 2020. View Article : Google Scholar : PubMed/NCBI
47	Bao L, Liu F, Guo HB, Li Y, Tan BB, Zhang WX and Peng YH: Naringenin inhibits proliferation, migration, and invasion as well as induces apoptosis of gastric cancer SGC7901 cell line by downregulation of AKT pathway. Tumour Biol. 37:11365–11374. 2016. View Article : Google Scholar : PubMed/NCBI
48	Md S, Alhakamy NA, Aldawsari HM, Husain M, Kotta S, Abdullah ST, Fahmy UA, Alfaleh MA and Asfour HZ: Formulation design, statistical optimization, and in vitro evaluation of a naringenin nanoemulsion to enhance apoptotic activity in A549 lung cancer cells. Pharmaceuticals (Basel). 13:1522020. View Article : Google Scholar : PubMed/NCBI
49	Arul D and Subramanian P: Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. Pathol Oncol Res. 19:763–770. 2013. View Article : Google Scholar : PubMed/NCBI
50	Yan N, Wen L, Peng R, Li H, Liu H, Peng H, Sun Y, Wu T, Chen L, Duan Q, et al: Naringenin ameliorated kidney injury through Let-7a/TGFBR1 signaling in diabetic nephropathy. J Diabetes Res. 2016:87387602016. View Article : Google Scholar : PubMed/NCBI
51	Zhao Z, Jin G, Ge Y and Guo Z: Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways. Inflammopharmacology. 27:1021–1036. 2019. View Article : Google Scholar : PubMed/NCBI
52	Wang R, Wang J, Dong T, Shen J, Gao X and Zhou J: Naringenin has a chemoprotective effect in MDA-MB-231 breast cancer cells via inhibition of caspase-3 and −9 activities. Oncol Lett. 17:1217–1222. 2019.PubMed/NCBI
53	Wang Y, Liu Z, Liu Q, Han Y, Zang Y, Zhang H, Du X, Qin T and Wu Y: Honokiol suppressed pancreatic cancer progression via miR-101/Mcl-1 axis. Cancer Manag Res. 12:5243–5254. 2020. View Article : Google Scholar : PubMed/NCBI
54	Newton K, Wickliffe KE, Maltzman A, Dugger DL, Reja R, Zhang Y, Roose-Girma M, Modrusan Z, Sagolla MS, Webster JD and Dixit VM: Activity of caspase-8 determines plasticity between cell death pathways. Nature. 575:679–682. 2019. View Article : Google Scholar : PubMed/NCBI
55	Zhou J, Xia L and Zhang Y: Naringin inhibits thyroid cancer cell proliferation and induces cell apoptosis through repressing PI3K/AKT pathway. Pathol Res Pract. 215:1527072019. View Article : Google Scholar : PubMed/NCBI
56	Lim W, Park S, Bazer FW and Song G: Naringenin-induced apoptotic cell death in prostate cancer cells is mediated via the PI3K/AKT and MAPK signaling pathways. J Cell Biochem. 118:1118–1131. 2017. View Article : Google Scholar : PubMed/NCBI